Back to today’s briefing

Story perspectives

Bristol Myers Squibb Cuts $2B, Lays Off 2,200 Employees

2/6/2025

23 2

Summary

Story summary

Bristol Myers Squibb will reduce costs by an additional $2 billion by 2027, building on a prior $1.5 billion plan.
Approximately 2,200 employees, or 6% of the workforce, will be laid off as part of the restructuring.
Revenue is expected to decline to $45.5 billion in 2025, primarily due to generic drug competition.
BMS plans to reinvest savings into growth sectors, focusing on oncology and cardiovascular treatments.

History

Historical Context

Bristol Myers Squibb's $2 billion cost-cutting plan echoes past industry shifts, notably the 2009 restructuring aimed at adapting to generic competition. Similar to earlier layoffs, this move reflects the ongoing struggle of pharmaceutical giants to maintain profitability amidst evolving market dynamics and increasing pressure from generic drugs.

1 of 2

Story summary

Bristol Myers Squibb will reduce costs by an additional $2 billion by 2027, building on a prior $1.5 billion plan.
Approximately 2,200 employees, or 6% of the workforce, will be laid off as part of the restructuring.
Revenue is expected to decline to $45.5 billion in 2025, primarily due to generic drug competition.
BMS plans to reinvest savings into growth sectors, focusing on oncology and cardiovascular treatments.

1 / 2